CD47-amyloid-β-CD74 signaling is a key driver of adaptive immunosuppression in sepsis, suppressing B cells and impairing ...

Measles doesn’t just cause illness, but also erases the immune system’s memory, leaving people vulnerable to infections ...

Advances Amgen’s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, CA, USA I April 3, 2025 I Amgen (NASDAQ:AMGN) ...

Negative blood types are particularly valuable because they are not common. With less than 2% (one in 50 donors) of the ...

a transcription factor necessary for the transient expansion of B cells preceding plasma cell differentiation, via coupling its translation to its decay. Recovery for mammalian retinal ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

The following is a summary of “BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma,” published in ...

US FDA approves Amgen’s Uplizna to treat IgG4-related disease: Thousand Oaks, California Saturday, April 5, 2025, 11:00 Hrs [IST] Amgen announced that the US Food and Drug Admin ...